Want to see AMGN full AI Analyst Report?

Amgen (AMGN) Stock Forecast & Price Target

6,940 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMGN Analyst Ratings

Moderate Buy

10 Buy

10 Hold

2 Sell

Based on 22 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMGN Stock 12 Month Forecast

Average Price Target

$380.19

▲(1.10% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $380.19 with a high forecast of $452.00 and a low forecast of $230.00. The average price target represents a 1.10% change from the last price of $376.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"229":"$229","285":"$285","341":"$341","397":"$397","453":"$453"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":452,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$452.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":380.1904761904762,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$380.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":230,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$230.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[229,285,341,397,453],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,385.16,390.3015384615385,395.44307692307694,400.5846153846154,405.72615384615386,410.8676923076923,416.0092307692308,421.15076923076924,426.2923076923077,431.43384615384616,436.5753846153846,441.7169230769231,446.85846153846154,{"y":452,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,385.16,384.77772893772897,384.3954578754579,384.01318681318685,383.6309157509158,383.24864468864473,382.8663736263737,382.48410256410256,382.1018315018315,381.71956043956044,381.3372893772894,380.9550183150183,380.57274725274726,{"y":380.1904761904762,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,385.16,373.2246153846154,361.2892307692308,349.3538461538462,337.41846153846154,325.48307692307696,313.54769230769233,301.6123076923077,289.6769230769231,277.7415384615385,265.80615384615385,253.87076923076924,241.93538461538463,{"y":230,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":288.216,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":292.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":292.071,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332.655,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":322.621,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":339.742,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":382.809,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":350.632,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.348,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":329.13,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":361.33,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":385.16,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$452.00

Average Price Target$380.19

Lowest Price Target$230.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yaron Werber

TD Cowen

$420→$452

Buy

20.20%

Upside

Reiterated

08/05/26

TD Cowen Sticks to Its Buy Rating for Amgen (AMGN)

Jay Olson

Oppenheimer

$400→$450

Buy

19.67%

Upside

Reiterated

08/05/26

Amgen price target raised to $450 from $400 at OppenheimerAmgen price target raised to $450 from $400 at Oppenheimer

David Amsellem

Piper Sandler

$427

Buy

13.55%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Exagen (NASDAQ: XGN), Amgen (NASDAQ: AMGN) and Arvinas Holding Company (NASDAQ: ARVN)

Gregory Renza

Truist Financial

$340→$362

Hold

-3.73%

Downside

Reiterated

08/05/26

Truist Financial Reaffirms Their Hold Rating on Amgen (AMGN)

Geoff Meacham

Citi

$345

Hold

-8.25%

Downside

Reiterated

08/05/26

Citi Keeps Their Hold Rating on Amgen (AMGN)

Terence Flynn

Morgan Stanley

$333→$351

Hold

-6.66%

Downside

Assigned

08/05/26

Terence Flynn Reaffirms Hold on Amgen as Strong Q2 Results and 2026 Guidance Boost Outlook, Price Target Raised from $333 to $351

Salveen Richter

Goldman Sachs

$427→$450

Buy

19.67%

Upside

Reiterated

08/05/26

Analysts' Top Healthcare Picks: Amgen (AMGN), Eli Lilly & Co (LLY)

Evan Seigerman

BMO Capital

$400→$450

Buy

19.67%

Upside

Reiterated

08/05/26

Amgen price target raised to $450 from $400 at BMO CapitalAmgen price target raised to $450 from $400 at BMO Capital

Courtney Breen

Bernstein

$335→$345

Hold

-8.25%

Downside

Reiterated

08/05/26

Bernstein Reaffirms Their Hold Rating on Amgen (AMGN)

Tazeen Ahmad

Bank of America Securities

$312→$317

Sell

-15.70%

Downside

Reiterated

08/05/26

Amgen price target raised to $317 from $312 at BofAAmgen price target raised to $317 from $312 at BofA

Louise Chen

Scotiabank

$450

Buy

19.67%

Upside

Reiterated

08/05/26

Amgen (AMGN) Receives a Buy from Scotiabank

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/05/26

Analyst Maintains Buy on Amgen After Strong Q2 Beat, Raised Guidance and Multiple Late-Stage Pipeline Catalysts

Michael Yee

UBS

$420→$440

Buy

17.01%

Upside

Reiterated

08/05/26

UBS Keeps Their Buy Rating on Amgen (AMGN)

Gary Nachman

Canaccord Genuity

$366→$384

Hold

2.12%

Upside

Reiterated

08/05/26

Amgen price target raised to $384 from $366 at CanaccordAmgen price target raised to $384 from $366 at Canaccord

Luca Issi

RBC Capital

$370→$400

Buy

6.37%

Upside

Reiterated

08/05/26

RBC Capital Sticks to Their Buy Rating for Amgen (AMGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yaron Werber

TD Cowen

$420→$452

Buy

20.20%

Upside

Reiterated

08/05/26

TD Cowen Sticks to Its Buy Rating for Amgen (AMGN)

Jay Olson

Oppenheimer

$400→$450

Buy

19.67%

Upside

Reiterated

08/05/26

Amgen price target raised to $450 from $400 at OppenheimerAmgen price target raised to $450 from $400 at Oppenheimer

David Amsellem

Piper Sandler

$427

Buy

13.55%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Exagen (NASDAQ: XGN), Amgen (NASDAQ: AMGN) and Arvinas Holding Company (NASDAQ: ARVN)

Gregory Renza

Truist Financial

$340→$362

Hold

-3.73%

Downside

Reiterated

08/05/26

Truist Financial Reaffirms Their Hold Rating on Amgen (AMGN)

Geoff Meacham

Citi

$345

Hold

-8.25%

Downside

Reiterated

08/05/26

Citi Keeps Their Hold Rating on Amgen (AMGN)

Terence Flynn

Morgan Stanley

$333→$351

Hold

-6.66%

Downside

Assigned

08/05/26

Terence Flynn Reaffirms Hold on Amgen as Strong Q2 Results and 2026 Guidance Boost Outlook, Price Target Raised from $333 to $351

Salveen Richter

Goldman Sachs

$427→$450

Buy

19.67%

Upside

Reiterated

08/05/26

Analysts' Top Healthcare Picks: Amgen (AMGN), Eli Lilly & Co (LLY)

Evan Seigerman

BMO Capital

$400→$450

Buy

19.67%

Upside

Reiterated

08/05/26

Amgen price target raised to $450 from $400 at BMO CapitalAmgen price target raised to $450 from $400 at BMO Capital

Courtney Breen

Bernstein

$335→$345

Hold

-8.25%

Downside

Reiterated

08/05/26

Bernstein Reaffirms Their Hold Rating on Amgen (AMGN)

Tazeen Ahmad

Bank of America Securities

$312→$317

Sell

-15.70%

Downside

Reiterated

08/05/26

Amgen price target raised to $317 from $312 at BofAAmgen price target raised to $317 from $312 at BofA

Louise Chen

Scotiabank

$450

Buy

19.67%

Upside

Reiterated

08/05/26

Amgen (AMGN) Receives a Buy from Scotiabank

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/05/26

Analyst Maintains Buy on Amgen After Strong Q2 Beat, Raised Guidance and Multiple Late-Stage Pipeline Catalysts

Michael Yee

UBS

$420→$440

Buy

17.01%

Upside

Reiterated

08/05/26

UBS Keeps Their Buy Rating on Amgen (AMGN)

Gary Nachman

Canaccord Genuity

$366→$384

Hold

2.12%

Upside

Reiterated

08/05/26

Amgen price target raised to $384 from $366 at CanaccordAmgen price target raised to $384 from $366 at Canaccord

Luca Issi

RBC Capital

$370→$400

Buy

6.37%

Upside

Reiterated

08/05/26

RBC Capital Sticks to Their Buy Rating for Amgen (AMGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

ZURAZura Bio

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months

David AmsellemPiper Sandler

Success Rate

13/18 ratings generated profit

Average Return

+6.11%

Copying David Amsellem's trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +6.11% per trade.

1 Year

David AmsellemPiper Sandler

Success Rate

18/18 ratings generated profit

Average Return

+22.62%

Copying David Amsellem's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.62% per trade.

2 Years

Salveen RichterGoldman Sachs

Success Rate

18/18 ratings generated profit

Average Return

+29.59%

Copying Salveen Richter's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +29.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMGN Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMGN has received 18 Buy Ratings, 19 Hold Ratings, and 3 Sell Ratings. AMGN average Analyst price target in the past 3 months is 380.19.

Each month's total comprises the sum of three months' worth of ratings.

AMGN Financial Forecast

AMGN Earnings Forecast

Next quarter’s earnings estimate for AMGN is $5.81 with a range of $5.48 to $6.16. The previous quarter’s EPS was $6.29. AMGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.20% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.

AMGN Sales Forecast

Next quarter’s sales forecast for AMGN is $9.94B with a range of $9.57B to $10.27B. The previous quarter’s sales results were $10.10B. AMGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.28% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.

AMGN Stock Forecast FAQ

What is AMGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen Inc’s 12-month average price target is 380.19.

What is AMGN’s upside potential, based on the analysts’ average price target?

Amgen Inc has 1.10% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AMGN a Buy, Sell or Hold?

Amgen Inc has a consensus rating of Moderate Buy which is based on 10 buy ratings, 10 hold ratings and 2 sell ratings.

What is Amgen Inc’s price target?

The average price target for Amgen Inc is 380.19. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $452.00 ,the lowest forecast is $230.00. The average price target represents 1.10% Increase from the current price of $376.04.

What do analysts say about Amgen Inc?

Amgen Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of AMGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Amgen (AMGN) Stock Forecast & Price Target

AMGN Analyst Ratings

AMGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

AMGN Analyst Recommendation Trends

AMGN Financial Forecast

AMGN Earnings Forecast

AMGN Sales Forecast

AMGN Stock Forecast FAQ

Detailed List of Analyst Forecasts